Are there any modifiers to report 340B-acquired drugs to Medicare?


The Centers for Medicare & Medicaid Services (CMS) established the following HCPCS Level II modifiers to identify 340B-acquired drugs:

  • Modifier JG—drug or biological acquired with 340B drug pricing program discount
  • Modifier TB—drug or biological acquired with 340B drug pricing program discount, reported for informational purposes.

When applicable, providers are required to report either of these modifiers on outpatient prospective payment system (OPPS) claims (bill type 13X) beginning January 1, 2018. Even though modifier TB is an informational modifier, reporting is mandatory for applicable providers.


CPT® copyright 2021 American Medical Association (AMA). All rights reserved.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

CPT is a registered trademark of the American Medical Association.